H-TAPDNL^GYM-OH

Rif. 3D-PP48360

Informazioni sul prodotto

• Nome: H-TAPDNL^GYM-OH

Descrizione

Peptide H-TAPDNL^GYM-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-TAPDNL^GYM-OH include the following: The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion Y Zhang , HCJ Ertl - The Journal of Immunology, 2014 - journals.aai.orghttps://journals.aai.org/jimmunol/article/193/4/1836/97876 Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+ T cells within tumors Y Zhang , HCJ Ertl - Oncotarget, 2016 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029626/ Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models T Tada , TD Norton, R Leibowitz - for Immunotherapy of , 2024 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11043704/ Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity SK Dougan, M Dougan, J Kim, JA Turner , S Ogata - Cancer immunology , 2013 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/1/2/99/466749 Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH SJ Crowley, PT Bruck, MA Bhuiyan - Open , 2020 - royalsocietypublishing.orghttps://royalsocietypublishing.org/doi/abs/10.1098/rsob.190235 Directly Conjugated Single-Domain VHHs Targeting MHC Class II Prime T-Cell Responses Against Pancreatic Cancer Neoantigens S Dougan - 2020 - apps.dtic.milhttps://apps.dtic.mil/sti/citations/AD1101171 Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation RR Jenq, CG King, C Volk, D Suh - Blood, The Journal , 2009 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/113/7/1574/25971 TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers K Barrios, E Celis - Cancer Immunology, Immunotherapy, 2012 - Springerhttps://link.springer.com/article/10.1007/s00262-012-1259-8 BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses HI Cho, K Barrios, YR Lee, AK Linowski - Cancer Immunology , 2013 - Springerhttps://link.springer.com/article/10.1007/s00262-012-1382-6 Sustained persistence of IL2 signaling enhances the antitumor effect of peptide vaccines through T-cell expansion and preventing PD-1 inhibition H Sultan , T Kumai, VI Fesenkova, AE Fan , J Wu - Cancer immunology , 2018 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/6/5/617/466707 Lipid accumulation and dendritic cell dysfunction in cancer DL Herber, W Cao, Y Nefedova , SV Novitskiy - Nature medicine, 2010 - nature.comhttps://www.nature.com/articles/nm.2172 Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy AS Huynh, WJ Chung, HI Cho, VE Moberg - Journal of medicinal , 2012 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/jm301002f Keratinocyte growth factor enhances DNA plasmid tumor vaccine AM Holland, SX Lu , JL Zakrzewski, GL Goldberg - researchgate.nethttps://www.researchgate.net/profile/Gabrielle-Goldberg-2/publication/238764459_Keratinocyte_growth_factor_enhances_DNA_plasmid_tumor_vaccine_responses_following_murine_allogeneic_bone_marrow_transplantation/links/0f31752d74c5b13e7d000000/Keratinocyte-growth-factor-enhances-DNA-plasmid-tumor-vaccine-responses-following-murine-allogeneic-bone-marrow-transplantation.pdf PPARalpha agonist fenofibrate enhances cancer vaccine efficacy A Chekaoui , HCJ Ertl - Cancer Research, 2021 - AACRhttps://aacrjournals.org/cancerres/article-abstract/81/17/4431/670278

• Marchio: Biosynth